Moon Shot concentrates on treating, preventing high-risk multiple myeloma
Multiple myeloma is the second most common hematological malignancy in the United States, and it’s increasing in incidence. An estimated 32,110 new cases will be diagnosed in 2019, with nearly 13,000 deaths caused by the disease. Certain patients have what is known as high-risk multiple myeloma (HRMM), meaning they have distinct molecular features that lead to more rapid progression and poorer outcomes.
The High-Risk Multiple Myeloma...
Combination chemotherapy before blood stem cell transplant improves progression-free survival
A randomized Phase III clinical trial combining two common chemotherapy agents as a pre-stem cell transplant treatment at The University of...
New therapies for follicular lymphoma on the horizon
Recently approved targeted and immunotherapy drugs are helping patients diagnosed with follicular lymphoma live longer. Knowing the available...
Utilizing the body’s natural born killers to take out blood cancers
Natural killer cells sound menacing, but they play a friendly role in keeping us healthy. And they might do much more in stopping cancer.
After years of diligent, groundbreaking research, MD Anderson physician-scientists are putting natural killer cells – NK cells for short – to work in a series of clinical trials for a variety of cancers through the cancer center’s Moon Shots Program™.
“These white...
Expanding the moon shots mission
MD Anderson’s Moon Shots Program has expanded its targets, adding some of the most intractable cancers to its campaign to more rapidly convert...
Analysis indicates blood cancer drugs are overpriced
The costs associated with cancer drug prices have risen dramatically over the past fifteen years, which concerns many top oncologists. In...